Sertraline induced galactorrhea.
Hyperprolactinemia may be observed secondary to various medical conditions. In psychiatry, it is an adverse effect that can be experienced during the use of some psychotropic drugs, particularly antipsychotics (1).
There are no controlled trials on antidepressant induced hyperprolactinemia; however there are some case reports in the literature. In these case reports, particularly hyperprolactinemia induced by paroxetine and escitalopram has been presented (2,3). In the literature, there are three case reports about galactorrhea associated with the use of sertraline. Bronzo and Stahl, in a case with major depressive disorder, have reported galactorrhea after a 5-week treatment using sertraline 100 mg/day. In this case, 3 weeks after the discontinuation of sertraline, galactorrhea vanished (4). Lesedi reported sertraline induced galactorrhea in a 40-year-old female with a diagnosis of major depressive disorder (5). In another case by Nebhinani, galactorrhea evolved on the 16th day of sertraline treatment in a patient with dysthymic disorder (6).
Hyperprolactinemia associated with the use of selective serotonin reuptake inhibitors (SSRI) is explained by the direct stimulation of postsynaptic serotonergic receptors in the hypothalamus and the serotonergic inhibition of dopamine, which is a prolactin inhibiting factor (4). Galactorrhea without an increase in prolactin may be caused by the indirect inhibition of tuberoinfundibular dopaminergic neurons (7). SSRIs were found about eight times more risky than other antidepressants for the induction of lactation (8). It has been reported that hyperprolactinemia causes sexual dysfunction, decrease in bone density, infertility, depression, and anxiety (9). These negative results require rigorous questioning of galactorrhea and amenorrhea in patients using antipsychotics and antidepressants.
In this article, we present the case of a patient diagnosed with adjustment disorder (with mixed anxiety-depressive mood) and galactorrhea on the 13rd day of sertraline treatment and will discuss the effects of sertraline on dopaminergic system.
A 34-year-old, married female admitted for psychiatric examination with complaints of distress, crying, and anhedonia ongoing for 6 weeks. The patient's complaints started after a relationship crisis. On her mental state examination, her behavior and mood were anxious and depressive. Her thought process consisted of problems with her husband. There was no perception and memory impairment. Her intelligence seemed to be clinically normal; furthermore, she developed insights. Her appetite and libido decreased; however, she had no sleep disorder Neither she nor her family has a history of psychiatric diseases. She does not smoke and use any psychoactive substance. Alcohol use is at the level of social drinking. Biochemistry, complete blood count, thyroid function tests, and vitamin B12 and folic acid levels were normal. Cranial magnetic resonance (MR) imaging showed no pathology. Hamilton Depression Rating Scale-17 items (HDRS), Hamilton Anxiety Scale (HAS), and Beck Depression Scale (BDS) scores were 18, 12, and 24, respectively.
The patient was diagnosed with adjustment disorder (with mixed anxiety-depressive mood). Sertraline 25 mg/day oral treatment given besides couple psychotherapy. After a week, sertraline dose was increased to 50 mg/ day On the 13rd day of treatment, she complained of "flow of milk from both breasts" Galactorrhea was considered. Because neither obstetrics nor neurology consultation results showed hyperprolactinemia and/or adenoma in pituitary starting a dopamine agonist agent was not considered. Sertraline treatment was discontinued, and the patient was closely monitored. A week after the discontinuation of sertraline, galactorrhea diminished, and after 16 days totally disappeared. As patient's depressive symptoms remained, fluoxetine 20 mg/day oral treatment was initiated. During the followup, two months after fluoxetine treatment, no galactorrhea was observed. There was a significant improvement in depressive symptoms and relationship issues of the patient whose psychotherapy process still continues. Her HDRS, HAS, and BDS scores were 11, 6, and 9.
Each of the antidepressants belonging to SSRI group has different neurochemical features, and differ in binding to noradrenaline, dopamine, and muscarinic receptors and carriers (10). Recent researches suggest that sertraline inhibits dopamine reuptake, whereas paroxetine reduces noradrenaline reuptake in rats (11). In a study Kitaichi et al. (12) investigated the changes in monoamines and metabolites in different regions of the brain after antidepressant application in rats. They observed that dopamine levels in nucleus accumbens, and striatum increased after sertraline application. In rats given fluvoxamine and paroxetine, a similar dopamine increase was not observed. In another study with sertraline as well as with venlafaxine and duloxetine, a similar dopamine increase was reported in rats (13). Dopamine reuptake inhibition observed after sertraline administration in in vivo experiments seems to be parallel to the dopamine increase in nucleus accumbens and striatum of rats observed after sertraline intake. However to date, the association between antidepressant efficacy and these pharmacological properties is not known.
Today although serotonin and noradrenaline stand in the forefront of the biological basis of depression, recent studies make us think that dopamine plays a prominent role in the biological mechanism of depression and the efficacy of antidepressant treatments (14). Various researches suggested encouraging results of dopamine agonists bromocriptine and pergolide combined with an antidepressant in treatment resistant depression (15,16). If increased dopamine levels associated with the effects of sertraline in the mesolimbic reward system are observed, sertraline provides antidepressant efficacy superior to other SSRIs. In a meta-analysis that compared the efficacy of antidepressants, Cipriani et al. (17) reported that sertraline has higher antidepressant efficacy than other SSRIs. The reason of this superiority may be the dopaminergic effect observed in sertraline, and in our case, responsible for galactorrhea.
In conclusion, sertraline is an SSRI that has an impact on dopaminergic system. This neurochemical property may be responsible for galactorrhea associated with sertraline, and also may provide antidepressant efficacy superior to other SSRIs.
Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The authors declared that this study has received no financial support.
(1.) Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35:75-86. [CrossRef]
(2.) Chakraborty S, Sanyal D, Bhattacharyya R, Dutta A. A case of paroxetine-induced galactorrhoea with normal serum prolactin level. Indian J Pharmacol 2010; 42:322-323. [CrossRef]
(3.) Belli H, Vardar MK, Yesilyurt S, Gul ES, Ural C. Citalopram related euprolactinaemic galactorrhoea: a case report. West Indian Med J 2010; 59:100-111.
(4.) Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry 1993; 150:1269-1270. [CrossRef]
(5.) Lesaca TG. Sertraline and galactorrhea. J Clin Psychopharmacol 1996; 16:333-334. [CrossRef]
(6.) Nebhinani N. Sertraline-induced galactorrhea: case report and review of cases reported with other SSRIs. Gen Hosp Psychiatry. 2012; pii: S0163-8343(12)00328-3.
(7.) Mahasuar R, Majhi P, Ravan JR. Euprolactinemic galactorrhea associated with use of imipramine and escitalopram in a postmenopausal woman. Gen Hosp Psychiatry 2010; 32:11-13. [CrossRef]
(8.) Egberts AC, Meyboom RH, Koning FH, Bakker A, Leufkens HG. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 1997; 44:277-281. [CrossRef]
(9.) Edge DS, Segatore M . Assessment and management of galactorrhea. Nurse Pract 1993; 18:35-49. [CrossRef]
(10.) Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50:345-350. [CrossRef]
(11.) Goodnick PJ, GoldsteinBJ. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J Psychopharmacol 1998; 12:5-20.
(12.) Kitaichi Y Inoue T Nakagawa S, Boku S, Kakuta A, Izumi T Koyama T Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 2010; 647:90-96. [CrossRef]
(13.) Muneoka K, Shirayama Y Takigawa M, Shioda S. Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochem Res 2009; 34:542-555. [CrossRef]
(14.) Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006; 16:391-402. [CrossRef]
(15.) Izumi T Inoue T Kitagawa N, Nishi N, Shimanaka S, Takahashi Y Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61:127-132. [CrossRef]
(16.) Inoue T Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T Koyama T Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996; 40:151-153. [CrossRef]
(17.) Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746-758. [CrossRef]
Eylem OZTEN, Gokben HIZLI SAYAR, Isil GOGCEGOZ GUL, Mehmet Emin CEYLAN
Department of Psychology, Uskudar University, Humanities and Social Sciences Faculty, Istanbul, Turkey
Correspondence Address: Dr. Gokben Hizli Sayar, Department of Psychology, Uskudar University, Humanities and Social Sciences Faculty, Istanbul, Turkey Phone: +90 530 244 13 16 E-mail: firstname.lastname@example.org
Received: 05.07.2013 Accepted: 02.12.2013
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Case Report|
|Author:||Ozten, Eylem; Sayar, Gokben Hizli; Gul, Isil Gogcegoz; Ceylan, Mehmet Emin|
|Publication:||Archives of Neuropsychiatry|
|Date:||Jun 1, 2015|
|Previous Article:||Neuro-Behcet's disease with chorea.|
|Next Article:||Treatment approach to sleep terror: two case reports.|